Officials with the FDA have approved tildrakizumab-asmn, (Ilumya, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis, according to the manufacturer. In a statement released Wednesday announcing the approval, SunPharma said the medication is intended for patients who are candidates for systemic therapy or phototherapy.
Psoriasis is a chronic dermatologic disease that develops when a person’s immune system sends faculty signals, causing skins cells to grow too quickly. According to the American Academy of Dermatology, the body does not shed the excess skin cells, which causes them to build on the surface of the skin and creating raised, reddish patches with a white coating. Plaque psoriasis is the most common form of the condition with patches most often appearing on the knees, elbows, lower back and scalp. These patches are often itchy and painful, and can crack and bleed.